NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program

Rezera plans to advance ruvonoflast into a Phase 3 clinical trial in peripheral artery disease (PAD) in H1 of 2027

Boston, MA, September 9, 2026 – NodThera Inc. (the "Company"), a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases, today announced that it is changing its name to Rezera Inc., effective immediately. The Company also announced that it plans to initiate Phase 3 development of ruvonoflast, its lead NLRP3 inhibitor, in peripheral artery disease (PAD) as its lead cardiovascular indication. These announcements mark important milestones in the Company's progress toward establishing the first approval for ruvonoflast in cardiovascular disease.

Rezera has evolved from a leader in NLRP3 science into a clinical-stage biotechnology company focused on translating innate immunology science into therapies that can safely and robustly reduce central and peripheral inflammation in cardiovascular and neurologic diseases. In preparation for initiating registrational studies, obtaining regulatory approval, and commercial launch, the Company recently strengthened its management team with appointments of Geoff McDonough, M.D., as Chief Executive Officer, Chris Guiffre, J.D., M.B.A., as Chief Financial Officer, and Jyothis George, MBBS, Ph.D., as Chief Medical Officer.

"Our new name reflects our determination to resolve chronic inflammation in the early stages of cardiovascular and neurologic disease," said Geoff McDonough, M.D., Chief Executive Officer of Rezera. "We believe ruvonoflast can lead a new era in anti-inflammatory therapy in PAD, and it could be the first disease-modifying therapy for a condition that impacts 230 million people worldwide. Most patients with PAD have elevated markers of chronic inflammation, yet they have been overlooked by drug developers for over two decades. Rezera is here to change that."

Today, Rezera will announce topline results from the Phase 2 RESOLVE-1 clinical trial of ruvonoflast, which enrolled 176 participants with and without type 2 diabetes. The RESOLVE-1 results, together with previously published data in participants with elevated cardiovascular risk and high inflammatory burden[1], and data in participants with neuroinflammation[2], make up a clinical dataset comprising more than 400 participants enrolled across five ruvonoflast clinical trials. Rezera has gained regulatory alignment on the core elements of the Phase 3 trial for ruvonoflast, providing a strong foundation for advancing the therapy to a registrational study in PAD in the first half of 2027.

About Peripheral Artery Disease

PAD is a common, serious form of atherosclerotic cardiovascular disease in which narrowed arteries reduce blood flow to the limbs, most often the legs, significantly reducing quality of life, walking performance and functional status as the disease progresses. In early stages of PAD, patients have an approximately two-fold increased risk of cardiovascular death, rising to approximately four-fold in later-stage disease.

About Rezera

Rezera is a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and

neurologic diseases driven by the NLRP3 inflammation pathway. The Company's lead program, ruvonoflast (f/k/a NT-0796), recently completed its Phase 2 RESOLVE-1 and RESOLVE-2 trials. The Company expects to commence a Phase 3 registrational study of ruvonoflast in H1 of 2027. The Company is also advancing trabzanoflast (f/k/a NT-0150) for treatment of neurologic diseases and expects to communicate Phase 1 topline results in Q4 of 2026.

Rezera is headquartered in Boston, Massachusetts, with an R&D base in Cambridge, UK.

Learn more at www.Rezera.com or follow the Company on LinkedIn.

Investors and Media
Argot Partners
Rezera@argotpartners.com

1 Ray KK, Clarke N, Thornton P, Miles AE, Digby Z, Davies MJ, Gorman M, Mullen B, Reader V, Magill M, Johnstone H, Ariti C, Sattar N, Marx N, Navar AM, Hernandez AF, George JT, Watt AP, Butler J, Ridker PM. Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk. JACC. 2026. https://doi.org/10.1016/j.jacc.2026.05.014

2 Clarke, N., Thornton, P., Reader, V., Lindsay, N., Digby, Z., Mullen, B., Gorman, M., Jacobson, E., Langdon, G., Johnstone, H., Wheeler, A. and Watt, A.P. (2025), Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease. Mov Disord, 40: 2199-2208. https://doi.org/10.1002/mds.30307